Understanding the progression of advanced medullary thyroid cancer
Utilization of the Natural History of Medullary Thyroid Carcinoma to Inform Advanced Disease Management
This study is trying to learn more about how advanced medullary thyroid cancer develops and affects patients' lives by collecting health information and feedback from those living with the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2030 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 2 sites (San Francisco, California and 1 other locations) |
| Trial ID | NCT04216732 on ClinicalTrials.gov |
What this trial studies
This observational study utilizes a multi-institutional registry to explore the natural history of advanced medullary thyroid cancer (MTC). It aims to collect and analyze demographic, clinical, pathologic, and genotypic data to understand how MTC develops and progresses. Patients will complete questionnaires about their health, quality of life, and the impact of the disease on their lives multiple times a year. The study also seeks to identify predictors of disease progression and evaluate patient-reported outcomes related to treatment adherence and quality of life.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with medullary thyroid cancer at any disease phase who are registrants in the Medullary Thyroid Cancer Registry.
Not a fit: Patients with early-stage medullary thyroid cancer or those not registered in the Medullary Thyroid Cancer Registry may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients with advanced medullary thyroid cancer.
How similar studies have performed: Other studies focusing on the natural history of cancer have shown success in improving understanding and management of the disease, making this approach promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aims 1 and 2: A diagnosis of MTC * Aims 1 and 2: A registrant in the Medullary Thyroid Cancer Registry (MTCR). Patients of all disease phases will be eligible for enrollment * Aim 3: A diagnosis of advanced phase (red or gray) MTC as determined by clinical team * Aim 3: A current registrant in the MTCR
Where this trial is running
San Francisco, California and 1 other locations
- University of California San Francisco — San Francisco, California, United States (Recruiting)
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Elizabeth G Grubbs — M.D. Anderson Cancer Center
- Study coordinator: Elizabeth G Grubbs
- Email: eggrubbs@mdanderson.org
- Phone: 713-792-6940
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.